As the field of pulmonary hypertension expands, sometimes issues arise where clinicians or scientists in the field desire additional guidance based on the currently available evidence, or in some cases, lack of published research on a particular subject. In those instances, PHA’s Scientific Leadership Council (SLC) convenes to analyze the issue, and from those interactions, Consensus Statements are developed.

The following statements on pulmonary hypertension medical issues were developed by the Education Committee of the SLC or its leadership, and were reviewed and approved by the SLC membership.

The SLC has also prepared Treatment Fact Sheets for information on specific PAH therapies.

PHA appreciates the work of the SLC's Education Committee in preparing and maintaining these documents. Originally developed by former Education Committee Chair Ivan Robbins, MD, they are annually reviewed and updated (if necessary) by the SLC Education Committee.


FacebookTwitterInstagram iconLinkedInYouTube

For optimal viewing of, please use a standards-compliant browser such as Google Chrome or Firefox.

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs. PHA does not endorse or recommend any commercial products or services.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Terms of Use    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2017 Pulmonary Hypertension Association. All Rights Reserved.

BBB Accredited Charity BEST in AmericaCharity Navigator

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.